Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources
Entry of 11 New High-Value Branded Agents and a Growing NSCLC Population Will Drive Market Growth, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that, from 2013 to 2018, the non-small-cell lung cancer (NSCLC) market in Argentina, Brazil and Mexico will increase at an annual rate of six percent, reaching $495 million in 2018.
The Emerging Markets report, Non-Small-Cell Lung Cancer in Argentina, Brazil, and Mexico, also finds that changes in medical practice and reimbursement and the resulting continued uptake of targeted therapies will drive growth in this market. The market will also be sustained by a growing incident population and by the launch of 11 new branded therapies, despite limitations imposed on drug cancer coverage within the public sector.
Between 2013 and 2018, 11 novel branded NSCLC therapies will launch in Argentina, Brazil, and Mexico--Pfizer's crizotinib (which launched in Argentina and Mexico in March 2013 under brand name Xalkori), Celgene's nanoparticle paclitaxel, Boehringer Ingelheim's afatinib, Pfizer's dacomitinib, Novartis's ceritinib, Boehringer Ingelheim's nintedanib, Bristol-Myers Squibb's nivolumab, Roche's onartuzumab, Pfizer's dacomitinib, Eli Lilly's necitumumab, Eisai's eribulin and Merck & Co's MK-3475. Although the number of patients treated with these agents will be smaller compared to the world's major markets, the combined sales will comprise 16 percent of the total NSCLC market in 2018, owing to their high price.
The report, which includes primary research with Argentine, Brazilian and Mexican oncologists, also finds that the number of incident cases of NSCLC across the three geographies will increase by 25 percent between 2013 and 2023, because of an expanding and aging population and the strong association between risk and age.
"Out of the three countries, Brazil is the largest and most populated, with the highest incident population of NSCLC; it boasts the highest total sales of NSCLC therapies. But Argentina, with its wealthy population and good access to targeted therapies, was the undisputed leader of brand sales across the three markets, claiming over a half of all the brand sales in 2013," said Decision Resources Analyst Natalia Reoutova, M.A., M.Sc. "However, as targeted therapies and new branded agents experience greater uptake in Brazil and Mexico, Argentina's share of brand therapies becomes more diluted by 2018."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.